- BriaCell Therapeutics (TSX:BCT) has revealed new positive survival data in its Phase 2 metastatic breast cancer study
- Patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial had a one-year survival rate of 55 per cent
- This number exceeds the survival data of the current standard of care for similar patients
- Shares of BriaCell Therapeutics are up 2.70 per cent to C$1.14 as of 10:19 am ET
BriaCell Therapeutics (TSX:BCT) has revealed new positive survival data in its Phase 2 metastatic breast cancer study.
In a news release, the company revealed that 55 per cent of the patients treated with with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial had a one-year survival rate, while multiple patients had an overall survival of more than two years.
According to BriaCell, this number exceeds the survival data of the current standard of care for similar patients.
“BriaCell’s clinical data supports our hypothesis that our regimen has prolonged survival in patients with metastatic breast cancer who otherwise have not responded to currently available treatments,” William V. Williams, CEO of BriaCell Therapeutics, said in a statement. “We look forward to further confirming these impressive data in our ongoing pivotal Phase 3 study, with interim results expected in the second half of 2025. Overall survival is the primary endpoint in our pivotal Phase 3 study.”
The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT regimen plus checkpoint inhibitor.
Out of those 54 patients, 37 were treated with the formulation used in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer. The final median overall survival calculation for the Phase 2 study is pending because many patients are still alive.
Tuesday’s news comes a week after BriaCell updated on its Phase 3 study of Bria-IMT in combination with an immune check point inhibitor on metastatic breast cancer.
The company will enrol up to 354 patients, with enrolment expected to be completed by mid-2025. The study’s primary endpoint is overall survival with Bria-IMT regimen plus check point inhibitor versus treatment of a physician’s choice.
With headquarters out of Vancouver, BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to treat cancer.
Shares of BriaCell Therapeutics (TSX:BCT) are up 2.70 per cent to C$1.14 as of 10:19 am ET
Join the discussion: Find out what everybody’s saying about this stock on the BriaCell Therapeutics Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Shutterstock)